nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—dilated cardiomyopathy	0.619	1	CbGaD
Gefitinib—ALB—Furosemide—dilated cardiomyopathy	0.0422	0.38	CbGbCtD
Gefitinib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0367	0.33	CbGbCtD
Gefitinib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0323	0.291	CbGbCtD
Gefitinib—CYP2C9—cardial valve—dilated cardiomyopathy	0.0105	0.188	CbGeAlD
Gefitinib—CSNK1E—cardiac ventricle—dilated cardiomyopathy	0.00299	0.0534	CbGeAlD
Gefitinib—Ulcer—Spironolactone—dilated cardiomyopathy	0.00297	0.0336	CcSEcCtD
Gefitinib—Bosutinib—SIK1—dilated cardiomyopathy	0.00294	0.311	CrCbGaD
Gefitinib—MKNK2—cardiac ventricle—dilated cardiomyopathy	0.00274	0.049	CbGeAlD
Gefitinib—IRAK1—cardiac ventricle—dilated cardiomyopathy	0.00274	0.049	CbGeAlD
Gefitinib—MKNK1—cardiac ventricle—dilated cardiomyopathy	0.00271	0.0484	CbGeAlD
Gefitinib—CHEK2—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.0026	1	CbGdCrCtD
Gefitinib—MKNK2—myocardium—dilated cardiomyopathy	0.00258	0.0461	CbGeAlD
Gefitinib—IRAK1—myocardium—dilated cardiomyopathy	0.00258	0.0461	CbGeAlD
Gefitinib—MKNK1—myocardium—dilated cardiomyopathy	0.00255	0.0455	CbGeAlD
Gefitinib—Eruption—Furosemide—dilated cardiomyopathy	0.00249	0.0281	CcSEcCtD
Gefitinib—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00241	0.0272	CcSEcCtD
Gefitinib—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00231	0.0261	CcSEcCtD
Gefitinib—EGFR—heart—dilated cardiomyopathy	0.00204	0.0365	CbGeAlD
Gefitinib—CSNK1E—heart—dilated cardiomyopathy	0.00196	0.0351	CbGeAlD
Gefitinib—IRAK4—heart—dilated cardiomyopathy	0.00193	0.0345	CbGeAlD
Gefitinib—ERBB3—heart—dilated cardiomyopathy	0.00189	0.0339	CbGeAlD
Gefitinib—MAP2K5—myocardium—dilated cardiomyopathy	0.00187	0.0335	CbGeAlD
Gefitinib—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00184	0.0208	CcSEcCtD
Gefitinib—MKNK2—heart—dilated cardiomyopathy	0.0018	0.0322	CbGeAlD
Gefitinib—IRAK1—heart—dilated cardiomyopathy	0.0018	0.0322	CbGeAlD
Gefitinib—MKNK1—heart—dilated cardiomyopathy	0.00178	0.0318	CbGeAlD
Gefitinib—Lapatinib—EGFR—dilated cardiomyopathy	0.00175	0.185	CrCbGaD
Gefitinib—Drug interaction—Furosemide—dilated cardiomyopathy	0.00165	0.0186	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00156	0.0176	CcSEcCtD
Gefitinib—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00155	0.0175	CcSEcCtD
Gefitinib—Bosutinib—RPS6KB1—dilated cardiomyopathy	0.00154	0.163	CrCbGaD
Gefitinib—MKNK2—cardiac atrium—dilated cardiomyopathy	0.00154	0.0275	CbGeAlD
Gefitinib—MKNK1—cardiac atrium—dilated cardiomyopathy	0.00152	0.0272	CbGeAlD
Gefitinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.0015	0.0169	CcSEcCtD
Gefitinib—STK10—heart—dilated cardiomyopathy	0.00146	0.0262	CbGeAlD
Gefitinib—Bladder pain—Furosemide—dilated cardiomyopathy	0.00138	0.0156	CcSEcCtD
Gefitinib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00133	0.0151	CcSEcCtD
Gefitinib—MAP2K5—heart—dilated cardiomyopathy	0.00131	0.0234	CbGeAlD
Gefitinib—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00131	0.0148	CcSEcCtD
Gefitinib—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00129	0.0145	CcSEcCtD
Gefitinib—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00128	0.0145	CcSEcCtD
Gefitinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.00125	0.0141	CcSEcCtD
Gefitinib—Afatinib—EGFR—dilated cardiomyopathy	0.00124	0.131	CrCbGaD
Gefitinib—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00124	0.014	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00118	0.0133	CcSEcCtD
Gefitinib—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00116	0.0131	CcSEcCtD
Gefitinib—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00112	0.0127	CcSEcCtD
Gefitinib—MAP2K5—cardiac atrium—dilated cardiomyopathy	0.00112	0.02	CbGeAlD
Gefitinib—Malaise—Spironolactone—dilated cardiomyopathy	0.00111	0.0125	CcSEcCtD
Gefitinib—Cystitis—Lisinopril—dilated cardiomyopathy	0.00111	0.0125	CcSEcCtD
Gefitinib—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00104	0.0117	CcSEcCtD
Gefitinib—Dehydration—Furosemide—dilated cardiomyopathy	0.00103	0.0117	CcSEcCtD
Gefitinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00101	0.0114	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000999	0.0113	CcSEcCtD
Gefitinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000982	0.0111	CcSEcCtD
Gefitinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00094	0.0106	CcSEcCtD
Gefitinib—ALB—heart—dilated cardiomyopathy	0.000931	0.0166	CbGeAlD
Gefitinib—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.000927	0.0105	CcSEcCtD
Gefitinib—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00092	0.0164	CbGeAlD
Gefitinib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000879	0.00993	CcSEcCtD
Gefitinib—Erlotinib—EGFR—dilated cardiomyopathy	0.000874	0.0925	CrCbGaD
Gefitinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000866	0.00978	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000848	0.00958	CcSEcCtD
Gefitinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000809	0.00914	CcSEcCtD
Gefitinib—Urticaria—Spironolactone—dilated cardiomyopathy	0.000796	0.009	CcSEcCtD
Gefitinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000793	0.00896	CcSEcCtD
Gefitinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000774	0.00875	CcSEcCtD
Gefitinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000758	0.00857	CcSEcCtD
Gefitinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000753	0.0085	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00075	0.00847	CcSEcCtD
Gefitinib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000739	0.00835	CcSEcCtD
Gefitinib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000726	0.0082	CcSEcCtD
Gefitinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000718	0.00811	CcSEcCtD
Gefitinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000709	0.00802	CcSEcCtD
Gefitinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000706	0.00797	CcSEcCtD
Gefitinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000697	0.00787	CcSEcCtD
Gefitinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000686	0.00775	CcSEcCtD
Gefitinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000686	0.00775	CcSEcCtD
Gefitinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000668	0.00755	CcSEcCtD
Gefitinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000651	0.00736	CcSEcCtD
Gefitinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000645	0.00729	CcSEcCtD
Gefitinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000637	0.0072	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000636	0.00719	CcSEcCtD
Gefitinib—ABCG2—heart—dilated cardiomyopathy	0.000636	0.0114	CbGeAlD
Gefitinib—Rash—Spironolactone—dilated cardiomyopathy	0.000632	0.00714	CcSEcCtD
Gefitinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000632	0.00714	CcSEcCtD
Gefitinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000618	0.00698	CcSEcCtD
Gefitinib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000612	0.00691	CcSEcCtD
Gefitinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000607	0.00686	CcSEcCtD
Gefitinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000605	0.00684	CcSEcCtD
Gefitinib—CYP1A1—heart—dilated cardiomyopathy	0.000604	0.0108	CbGeAlD
Gefitinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000596	0.00673	CcSEcCtD
Gefitinib—CYP2C9—heart—dilated cardiomyopathy	0.000581	0.0104	CbGeAlD
Gefitinib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000576	0.00651	CcSEcCtD
Gefitinib—Vandetanib—EGFR—dilated cardiomyopathy	0.000576	0.0609	CrCbGaD
Gefitinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000569	0.00643	CcSEcCtD
Gefitinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000567	0.00641	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000565	0.00639	CcSEcCtD
Gefitinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000565	0.00638	CcSEcCtD
Gefitinib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000556	0.00629	CcSEcCtD
Gefitinib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000545	0.00615	CcSEcCtD
Gefitinib—Bosutinib—EGFR—dilated cardiomyopathy	0.000539	0.057	CrCbGaD
Gefitinib—Shock—Furosemide—dilated cardiomyopathy	0.000537	0.00606	CcSEcCtD
Gefitinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000535	0.00604	CcSEcCtD
Gefitinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000534	0.00603	CcSEcCtD
Gefitinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.00053	0.00599	CcSEcCtD
Gefitinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000523	0.00591	CcSEcCtD
Gefitinib—Anorexia—Furosemide—dilated cardiomyopathy	0.00052	0.00588	CcSEcCtD
Gefitinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000519	0.00587	CcSEcCtD
Gefitinib—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.000516	0.00923	CbGeAlD
Gefitinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000515	0.00581	CcSEcCtD
Gefitinib—Hypotension—Furosemide—dilated cardiomyopathy	0.00051	0.00576	CcSEcCtD
Gefitinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000509	0.00575	CcSEcCtD
Gefitinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000501	0.00567	CcSEcCtD
Gefitinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000474	0.00536	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000471	0.00532	CcSEcCtD
Gefitinib—Fatigue—Furosemide—dilated cardiomyopathy	0.00047	0.00531	CcSEcCtD
Gefitinib—Pain—Furosemide—dilated cardiomyopathy	0.000466	0.00527	CcSEcCtD
Gefitinib—Constipation—Furosemide—dilated cardiomyopathy	0.000466	0.00527	CcSEcCtD
Gefitinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000463	0.00524	CcSEcCtD
Gefitinib—Angioedema—Lisinopril—dilated cardiomyopathy	0.000458	0.00518	CcSEcCtD
Gefitinib—Malaise—Lisinopril—dilated cardiomyopathy	0.000452	0.00511	CcSEcCtD
Gefitinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000446	0.00504	CcSEcCtD
Gefitinib—Cough—Lisinopril—dilated cardiomyopathy	0.000438	0.00494	CcSEcCtD
Gefitinib—Urticaria—Furosemide—dilated cardiomyopathy	0.000433	0.0049	CcSEcCtD
Gefitinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000431	0.00487	CcSEcCtD
Gefitinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000431	0.00487	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000424	0.00479	CcSEcCtD
Gefitinib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000418	0.00472	CcSEcCtD
Gefitinib—Infection—Lisinopril—dilated cardiomyopathy	0.000407	0.00459	CcSEcCtD
Gefitinib—Shock—Lisinopril—dilated cardiomyopathy	0.000403	0.00455	CcSEcCtD
Gefitinib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000402	0.00454	CcSEcCtD
Gefitinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000401	0.00453	CcSEcCtD
Gefitinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000398	0.00449	CcSEcCtD
Gefitinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000391	0.00442	CcSEcCtD
Gefitinib—Anorexia—Lisinopril—dilated cardiomyopathy	0.00039	0.00441	CcSEcCtD
Gefitinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000386	0.00436	CcSEcCtD
Gefitinib—Hypotension—Lisinopril—dilated cardiomyopathy	0.000382	0.00432	CcSEcCtD
Gefitinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000373	0.00422	CcSEcCtD
Gefitinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000365	0.00412	CcSEcCtD
Gefitinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000356	0.00402	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000353	0.00399	CcSEcCtD
Gefitinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000353	0.00399	CcSEcCtD
Gefitinib—Pain—Lisinopril—dilated cardiomyopathy	0.00035	0.00395	CcSEcCtD
Gefitinib—Constipation—Lisinopril—dilated cardiomyopathy	0.00035	0.00395	CcSEcCtD
Gefitinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000347	0.00392	CcSEcCtD
Gefitinib—Rash—Furosemide—dilated cardiomyopathy	0.000344	0.00389	CcSEcCtD
Gefitinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000344	0.00388	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000335	0.00378	CcSEcCtD
Gefitinib—Urticaria—Lisinopril—dilated cardiomyopathy	0.000325	0.00367	CcSEcCtD
Gefitinib—Nausea—Furosemide—dilated cardiomyopathy	0.000324	0.00366	CcSEcCtD
Gefitinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000324	0.00366	CcSEcCtD
Gefitinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000324	0.00366	CcSEcCtD
Gefitinib—ABCB1—heart—dilated cardiomyopathy	0.000314	0.00561	CbGeAlD
Gefitinib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000302	0.00341	CcSEcCtD
Gefitinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000294	0.00332	CcSEcCtD
Gefitinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.00029	0.00327	CcSEcCtD
Gefitinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00028	0.00316	CcSEcCtD
Gefitinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.00026	0.00294	CcSEcCtD
Gefitinib—Rash—Lisinopril—dilated cardiomyopathy	0.000258	0.00292	CcSEcCtD
Gefitinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000258	0.00291	CcSEcCtD
Gefitinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000243	0.00275	CcSEcCtD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.74e-05	0.000505	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.74e-05	0.000505	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—RAC1—dilated cardiomyopathy	5.7e-05	0.000501	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	5.64e-05	0.000496	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	5.61e-05	0.000493	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.6e-05	0.000492	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—RAC1—dilated cardiomyopathy	5.56e-05	0.000489	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—RAF1—dilated cardiomyopathy	5.51e-05	0.000485	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	5.51e-05	0.000484	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—RAC1—dilated cardiomyopathy	5.47e-05	0.000481	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	5.41e-05	0.000476	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	5.41e-05	0.000476	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—RAF1—dilated cardiomyopathy	5.41e-05	0.000476	CbGpPWpGaD
Gefitinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	5.4e-05	0.000475	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—RAF1—dilated cardiomyopathy	5.36e-05	0.000471	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	5.35e-05	0.00047	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.34e-05	0.000469	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	5.32e-05	0.000467	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—RAF1—dilated cardiomyopathy	5.29e-05	0.000465	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—ITGB1—dilated cardiomyopathy	5.18e-05	0.000455	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.17e-05	0.000455	CbGpPWpGaD
Gefitinib—MKNK1—Disease—RAC1—dilated cardiomyopathy	5.17e-05	0.000454	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—RAF1—dilated cardiomyopathy	5.11e-05	0.000449	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	5.09e-05	0.000447	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD36—dilated cardiomyopathy	5.03e-05	0.000442	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.03e-05	0.000442	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.03e-05	0.000442	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—RAC1—dilated cardiomyopathy	5.03e-05	0.000442	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VCL—dilated cardiomyopathy	5.03e-05	0.000442	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.97e-05	0.000437	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.97e-05	0.000437	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.92e-05	0.000432	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—dilated cardiomyopathy	4.89e-05	0.00043	CbGpPWpGaD
Gefitinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	4.86e-05	0.000427	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	4.79e-05	0.000421	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—RAC1—dilated cardiomyopathy	4.74e-05	0.000417	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—RAF1—dilated cardiomyopathy	4.74e-05	0.000416	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—EGFR—dilated cardiomyopathy	4.71e-05	0.000414	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.68e-05	0.000411	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.66e-05	0.00041	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	4.63e-05	0.000407	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.62e-05	0.000406	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—EGFR—dilated cardiomyopathy	4.56e-05	0.000401	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—EGFR—dilated cardiomyopathy	4.54e-05	0.000399	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	4.51e-05	0.000396	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	4.48e-05	0.000394	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.48e-05	0.000393	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—ITGB1—dilated cardiomyopathy	4.47e-05	0.000393	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.43e-05	0.000389	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD36—dilated cardiomyopathy	4.42e-05	0.000388	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—dilated cardiomyopathy	4.35e-05	0.000382	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.27e-05	0.000375	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	4.26e-05	0.000374	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	4.24e-05	0.000372	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	4.18e-05	0.000367	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—RAC1—dilated cardiomyopathy	4.16e-05	0.000366	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ITGB1—dilated cardiomyopathy	4.13e-05	0.000363	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	4.1e-05	0.00036	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—RAC1—dilated cardiomyopathy	4.02e-05	0.000353	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.01e-05	0.000352	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	4e-05	0.000352	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	3.95e-05	0.000347	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	3.94e-05	0.000346	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.93e-05	0.000345	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.93e-05	0.000345	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	3.88e-05	0.000341	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	3.88e-05	0.000341	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	3.83e-05	0.000337	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.82e-05	0.000336	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—CD36—dilated cardiomyopathy	3.81e-05	0.000335	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	3.79e-05	0.000333	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.79e-05	0.000333	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.79e-05	0.000333	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—EGFR—dilated cardiomyopathy	3.78e-05	0.000332	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—RAF1—dilated cardiomyopathy	3.78e-05	0.000332	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—RAF1—dilated cardiomyopathy	3.69e-05	0.000324	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	3.69e-05	0.000324	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.65e-05	0.000321	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TAZ—dilated cardiomyopathy	3.65e-05	0.000321	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—RAF1—dilated cardiomyopathy	3.63e-05	0.000319	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.63e-05	0.000319	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.62e-05	0.000318	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	3.62e-05	0.000318	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—RAC1—dilated cardiomyopathy	3.59e-05	0.000316	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	3.57e-05	0.000314	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	3.57e-05	0.000314	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	3.56e-05	0.000313	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.55e-05	0.000312	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.54e-05	0.000311	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.52e-05	0.000309	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD36—dilated cardiomyopathy	3.52e-05	0.000309	CbGpPWpGaD
Gefitinib—EGFR—Disease—NPPA—dilated cardiomyopathy	3.5e-05	0.000308	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	3.48e-05	0.000306	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AGT—dilated cardiomyopathy	3.46e-05	0.000304	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ITGB1—dilated cardiomyopathy	3.44e-05	0.000302	CbGpPWpGaD
Gefitinib—MKNK1—Disease—RAF1—dilated cardiomyopathy	3.43e-05	0.000301	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.41e-05	0.0003	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	3.4e-05	0.000299	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	3.4e-05	0.000299	CbGpPWpGaD
Gefitinib—EGFR—Disease—PSEN2—dilated cardiomyopathy	3.39e-05	0.000298	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD36—dilated cardiomyopathy	3.37e-05	0.000296	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—RAF1—dilated cardiomyopathy	3.34e-05	0.000293	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.33e-05	0.000292	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	3.32e-05	0.000292	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—RAC1—dilated cardiomyopathy	3.32e-05	0.000292	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SDHA—dilated cardiomyopathy	3.3e-05	0.00029	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	3.28e-05	0.000288	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—EGFR—dilated cardiomyopathy	3.25e-05	0.000285	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD36—dilated cardiomyopathy	3.23e-05	0.000284	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	3.21e-05	0.000282	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.2e-05	0.000282	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	3.2e-05	0.000281	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	3.18e-05	0.000279	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—RAC1—dilated cardiomyopathy	3.17e-05	0.000279	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.15e-05	0.000277	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.15e-05	0.000277	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—RAF1—dilated cardiomyopathy	3.14e-05	0.000276	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.12e-05	0.000274	CbGpPWpGaD
Gefitinib—ERBB3—Disease—RAC1—dilated cardiomyopathy	3.06e-05	0.000269	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—RAC1—dilated cardiomyopathy	3.05e-05	0.000268	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.02e-05	0.000266	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	3.01e-05	0.000265	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	2.99e-05	0.000262	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	2.96e-05	0.00026	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.93e-05	0.000258	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD36—dilated cardiomyopathy	2.93e-05	0.000258	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.91e-05	0.000256	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	2.89e-05	0.000254	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.87e-05	0.000252	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.84e-05	0.00025	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—RAC1—dilated cardiomyopathy	2.82e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.76e-05	0.000243	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—RAC1—dilated cardiomyopathy	2.76e-05	0.000243	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—RAF1—dilated cardiomyopathy	2.76e-05	0.000242	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	2.74e-05	0.000241	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	2.72e-05	0.000239	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	2.7e-05	0.000237	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AGT—dilated cardiomyopathy	2.69e-05	0.000236	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—RAF1—dilated cardiomyopathy	2.67e-05	0.000234	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.61e-05	0.000229	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	2.6e-05	0.000229	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—EGFR—dilated cardiomyopathy	2.59e-05	0.000228	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.57e-05	0.000226	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	2.52e-05	0.000222	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.49e-05	0.000219	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.46e-05	0.000216	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.42e-05	0.000213	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.4e-05	0.000211	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—RAF1—dilated cardiomyopathy	2.38e-05	0.000209	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.37e-05	0.000209	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.37e-05	0.000209	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—dilated cardiomyopathy	2.35e-05	0.000207	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.3e-05	0.000202	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ITGB1—dilated cardiomyopathy	2.3e-05	0.000202	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—RAC1—dilated cardiomyopathy	2.23e-05	0.000196	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.21e-05	0.000194	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—RAF1—dilated cardiomyopathy	2.2e-05	0.000193	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—dilated cardiomyopathy	2.16e-05	0.00019	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—CD36—dilated cardiomyopathy	2.15e-05	0.000189	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.15e-05	0.000189	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.15e-05	0.000189	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AGT—dilated cardiomyopathy	2.13e-05	0.000187	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.11e-05	0.000185	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.11e-05	0.000185	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—RAF1—dilated cardiomyopathy	2.1e-05	0.000185	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.1e-05	0.000184	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AGT—dilated cardiomyopathy	2.05e-05	0.00018	CbGpPWpGaD
Gefitinib—ERBB3—Disease—RAF1—dilated cardiomyopathy	2.03e-05	0.000178	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—RAC1—dilated cardiomyopathy	2.03e-05	0.000178	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.02e-05	0.000178	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—RAF1—dilated cardiomyopathy	2.02e-05	0.000177	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.01e-05	0.000177	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.98e-05	0.000174	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.97e-05	0.000173	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.96e-05	0.000172	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.96e-05	0.000172	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD36—dilated cardiomyopathy	1.96e-05	0.000172	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.94e-05	0.00017	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AGT—dilated cardiomyopathy	1.93e-05	0.00017	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.9e-05	0.000167	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—dilated cardiomyopathy	1.89e-05	0.000166	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.89e-05	0.000166	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—RAF1—dilated cardiomyopathy	1.87e-05	0.000164	CbGpPWpGaD
Gefitinib—EGFR—Immune System—RAC1—dilated cardiomyopathy	1.85e-05	0.000162	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—RAF1—dilated cardiomyopathy	1.83e-05	0.000161	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—dilated cardiomyopathy	1.83e-05	0.000161	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.81e-05	0.000159	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.79e-05	0.000157	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.78e-05	0.000157	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.77e-05	0.000155	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.76e-05	0.000155	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.76e-05	0.000155	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AGT—dilated cardiomyopathy	1.71e-05	0.00015	CbGpPWpGaD
Gefitinib—EGFR—Disease—RAC1—dilated cardiomyopathy	1.71e-05	0.00015	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.68e-05	0.000148	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.65e-05	0.000145	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.65e-05	0.000145	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.62e-05	0.000142	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.6e-05	0.000141	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.58e-05	0.000139	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—dilated cardiomyopathy	1.55e-05	0.000137	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.54e-05	0.000135	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—dilated cardiomyopathy	1.51e-05	0.000133	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—RAF1—dilated cardiomyopathy	1.48e-05	0.00013	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	1.45e-05	0.000128	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.44e-05	0.000127	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.42e-05	0.000125	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	1.41e-05	0.000124	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—dilated cardiomyopathy	1.39e-05	0.000122	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.35e-05	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.34e-05	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.32e-05	0.000116	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—dilated cardiomyopathy	1.28e-05	0.000112	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	1.27e-05	0.000112	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—dilated cardiomyopathy	1.26e-05	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Immune System—RAF1—dilated cardiomyopathy	1.22e-05	0.000108	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RAC1—dilated cardiomyopathy	1.19e-05	0.000105	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.18e-05	0.000104	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.16e-05	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AGT—dilated cardiomyopathy	1.14e-05	0.0001	CbGpPWpGaD
Gefitinib—EGFR—Disease—RAF1—dilated cardiomyopathy	1.13e-05	9.94e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.04e-05	9.15e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.02e-05	8.97e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.01e-05	8.91e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—dilated cardiomyopathy	1.01e-05	8.89e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	9.83e-06	8.64e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—dilated cardiomyopathy	9.75e-06	8.57e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	9.58e-06	8.42e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	9.13e-06	8.02e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—dilated cardiomyopathy	8.96e-06	7.88e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CD36—dilated cardiomyopathy	8.73e-06	7.67e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	8.62e-06	7.58e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—dilated cardiomyopathy	8.12e-06	7.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	8.05e-06	7.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RAF1—dilated cardiomyopathy	7.92e-06	6.96e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGT—dilated cardiomyopathy	7.86e-06	6.91e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	7.85e-06	6.9e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	7.84e-06	6.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	7.65e-06	6.72e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	7.4e-06	6.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	7.34e-06	6.45e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	7.21e-06	6.33e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	7.15e-06	6.28e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	7.06e-06	6.2e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	6.89e-06	6.05e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	6.49e-06	5.7e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	6.43e-06	5.65e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.84e-06	4.25e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.71e-06	4.14e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	4.24e-06	3.73e-05	CbGpPWpGaD
